两株临床分离的光滑假丝酵母菌对两性霉素 B 的敏感性降低，均携带有 ERG2 基因突变。
Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.
机构信息
Institute of Life Science, Swansea University, Swansea, Wales, UK.
出版信息
Antimicrob Agents Chemother. 2012 Dec;56(12):6417-21. doi: 10.1128/AAC.01145-12. Epub 2012 Oct 1.
Abstract
Two novel isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B (MIC, 8 μg ml(-1)) were found to be ERG2 mutants, wherein Δ(8)-sterol intermediates comprised >90% of the total cellular sterol fraction. Both harbored an alteration at Thr(121) in ERG2; the corresponding residue (Thr(119)) in Saccharomyces cerevisiae is essential for sterol Δ8-Δ7 isomerization. This constitutes the first report of C. glabrata harboring mutations in ERG2 and exhibiting reduced sensitivity to amphotericin B.
摘要
发现两株新型近平滑假丝酵母（Candida glabrata）分离株对两性霉素 B 的敏感性降低（MIC，8μg/ml），它们是 ERG2 突变体，其中 Δ(8)-固醇中间产物占总细胞固醇部分的 >90%。这两个分离株都在 ERG2 的 Thr(121)处发生了改变；酿酒酵母（Saccharomyces cerevisiae）中相应的残基（Thr(119)）对于固醇 Δ8-Δ7 异构化是必需的。这是首例报道的携带 ERG2 突变并对两性霉素 B 敏感性降低的近平滑假丝酵母。
相似文献
1
Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin B both harbor mutations in ERG2.
Antimicrob Agents Chemother. 2012 Dec;56(12):6417-21. doi: 10.1128/AAC.01145-12. Epub 2012 Oct 1.
2
Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.
Antimicrob Agents Chemother. 2013 Jul;57(7):3182-93. doi: 10.1128/AAC.00555-13. Epub 2013 Apr 29.
3
Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.
Antimicrob Agents Chemother. 2012 Aug;56(8):4223-32. doi: 10.1128/AAC.06253-11. Epub 2012 May 21.
4
Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Antimicrob Agents Chemother. 2015 Oct 19;60(1):229-38. doi: 10.1128/AAC.02157-15. Print 2016 Jan.
5
In vitro activities of voriconazole, fluconazole, itraconazole and amphotericin B against non Candida albicans yeast isolates.
Rev Iberoam Micol. 2005 Mar;22(1):24-8. doi: 10.1016/s1130-1406(05)70002-4.
6
The activity of echinocandins, amphotericin B and voriconazole against fluconazole-susceptible and fluconazole-resistant Brazilian Candida glabrata isolates.
Mem Inst Oswaldo Cruz. 2012 May;107(3):433-6. doi: 10.1590/s0074-02762012000300022.
7
STB5 is a negative regulator of azole resistance in Candida glabrata.
Antimicrob Agents Chemother. 2013 Feb;57(2):959-67. doi: 10.1128/AAC.01278-12. Epub 2012 Dec 10.
8
Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.
Antimicrob Agents Chemother. 2018 Oct 24;62(11). doi: 10.1128/AAC.01131-18. Print 2018 Nov.
9
Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
Kaohsiung J Med Sci. 2012 Jun;28(6):306-15. doi: 10.1016/j.kjms.2011.11.011. Epub 2012 Apr 4.
10
Reliability of the Vitek 2 yeast susceptibility test for detection of in vitro resistance to fluconazole and voriconazole in clinical isolates of Candida albicans and Candida glabrata.
J Clin Microbiol. 2009 Jun;47(6):1927-30. doi: 10.1128/JCM.02070-08. Epub 2009 Apr 29.
引用本文的文献
1
Head-to-Head Comparison of Etest, MICRONAUT-AM EUCAST and Reference Broth Microdilution-Based CLSI Results for Antifungal Susceptibility Testing: Implications for Detection of Reduced Susceptibility to Amphotericin B.
J Fungi (Basel). 2025 Jul 30;11(8):570. doi: 10.3390/jof11080570.
2
Whole genome sequencing analysis of Candida glabrata isolates collected from patients with selected drug-resistant candidiasis hospitalized in Eastern Poland.
Folia Microbiol (Praha). 2025 Jul 14. doi: 10.1007/s12223-025-01298-w.
3
Monitoring of biofilm inhibition by using real-time impedance-based technology.
Curr Med Mycol. 2024 Nov 16;10. doi: 10.22034/cmm.2024.345240.1541. eCollection 2024.
4
Raman Imaging of an Amphotericin B Potentiator in Single-Cell .
J Phys Chem B. 2025 Jun 12;129(23):5720-5727. doi: 10.1021/acs.jpcb.5c02477. Epub 2025 May 30.
5
Antifungal drug resistance in Candida glabrata: role of cellular signaling and gene regulatory networks.
FEMS Yeast Res. 2025 Jan 30;25. doi: 10.1093/femsyr/foaf025.
6
Beyond Conventional Antifungals: Combating Resistance Through Novel Therapeutic Pathways.
Pharmaceuticals (Basel). 2025 Mar 4;18(3):364. doi: 10.3390/ph18030364.
7
Unveiling antifungal resistance and biocide tolerance in clinical isolates of spp.
Future Microbiol. 2025 Apr;20(6):457-468. doi: 10.1080/17460913.2025.2480924. Epub 2025 Mar 22.
8
Genetic interaction analysis of transcription factors and in the regulation of respiration and fluconazole susceptibility.
Antimicrob Agents Chemother. 2025 Feb 13;69(2):e0129424. doi: 10.1128/aac.01294-24. Epub 2024 Dec 23.
9
Candida auris MIC testing by EUCAST and clinical and laboratory standards institute broth microdilution, and gradient diffusion strips; to be or not to be amphotericin B resistant?
Clin Microbiol Infect. 2025 Jan;31(1):108-112. doi: 10.1016/j.cmi.2024.10.010. Epub 2024 Oct 18.
10
Evaluation of Etest and MICRONAUT-AM Assay for Antifungal Susceptibility Testing of : Underestimation of Fluconazole Resistance by MICRONAUT-AM and Overestimation of Amphotericin B Resistance by Etest.
Antibiotics (Basel). 2024 Sep 4;13(9):840. doi: 10.3390/antibiotics13090840.
本文引用的文献
1
Mutants with heteroresistance to amphotericin B and fluconazole in Candida.
Braz J Microbiol. 2009 Oct;40(4):943-51. doi: 10.1590/S1517-838220090004000028. Epub 2009 Dec 1.
2
Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B.
Antimicrob Agents Chemother. 2012 Aug;56(8):4223-32. doi: 10.1128/AAC.06253-11. Epub 2012 May 21.
3
Amphotericin primarily kills yeast by simply binding ergosterol.
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2234-9. doi: 10.1073/pnas.1117280109. Epub 2012 Jan 17.
4
Identification and characterization of four azole-resistant erg3 mutants of Candida albicans.
Antimicrob Agents Chemother. 2010 Nov;54(11):4527-33. doi: 10.1128/AAC.00348-10. Epub 2010 Aug 23.
5
A clinical isolate of Candida albicans with mutations in ERG11 (encoding sterol 14alpha-demethylase) and ERG5 (encoding C22 desaturase) is cross resistant to azoles and amphotericin B.
Antimicrob Agents Chemother. 2010 Sep;54(9):3578-83. doi: 10.1128/AAC.00303-10. Epub 2010 Jun 14.
6
Gain of function mutations in CgPDR1 of Candida glabrata not only mediate antifungal resistance but also enhance virulence.
PLoS Pathog. 2009 Jan;5(1):e1000268. doi: 10.1371/journal.ppat.1000268. Epub 2009 Jan 16.
7
A nonsense mutation in the ERG6 gene leads to reduced susceptibility to polyenes in a clinical isolate of Candida glabrata.
Antimicrob Agents Chemother. 2008 Oct;52(10):3701-9. doi: 10.1128/AAC.00423-08. Epub 2008 Aug 11.
8
Identification of essential amino acid residues in a sterol 8,7-isomerase from Zea mays reveals functional homology and diversity with the isomerases of animal and fungal origin.
Biochem J. 2008 Sep 1;414(2):247-59. doi: 10.1042/BJ20080292.
9
Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.
Clin Infect Dis. 2008 Jan 1;46(1):120-8. doi: 10.1086/524071.
10
Reduced susceptibility to polyenes associated with a missense mutation in the ERG6 gene in a clinical isolate of Candida glabrata with pseudohyphal growth.
Antimicrob Agents Chemother. 2007 Mar;51(3):982-90. doi: 10.1128/AAC.01510-06. Epub 2006 Dec 11.
Zotero 插件